Compare American Electric Power Company Inc (AEP) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs Amphastar Pharmaceuticals Inc — how do they compare? American Electric Power Company Inc trades at $123.55 (market cap $66.87B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: American Electric Power Company Inc is far larger — about 77.4× Amphastar Pharmaceuticals Inc's market cap, and American Electric Power Company Inc pays a 3.09% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AEP | AMPH | |
|---|---|---|
Market Cap | $66.87B | $863.95M |
Sector | Utilities | Health |
52-Week High | $138.69 | $30.81 |
52-Week Low | $106.44 | $16.87 |
Enterprise Value | $119.77B | $1.26B |
Dividend Yield | 3.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Electric Power (AEP) trades at $125.73, up 0.38% on the day, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings missed estimates at $1.36 per share versus $1.48 expected, though the company raised full-year 2026 operating EPS guidance to $6.25–$6.55, reflecting confidence in AI-driven power demand growth. Fundamentals show robust revenue growth to $21.88B in 2025 and a net income margin of 13.78%, supported by a $78 billion capital plan.
The outlook remains positive due to contracted load growth and infrastructure investments, but risks include execution of large capital expenditures and interest rate sensitivity. With a consensus price target of $140.89 and no sell ratings, Wall Street sentiment is bullish, though technical indicators suggest near-term caution amid bearish moving averages.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
